Pozen gains after positive PIII results for ulcer reducing aspirin, as partner search gains momentum
This article was originally published in Scrip
Pozen saw its share price surge as much as 19% in early trading on 22 March before closing up 8.8%, or $0.42, to $5.22 after reporting positive top-line data from its Phase III pivotal trials for its novel gastrointestinal-friendly aspirin candidate PA32540. The news added $11.6 million to the company's value at $143.6 million. The company is developing PA32540 for the secondary prevention of cardiovascular disease in patients that are at risk for aspirin-associated GI complications.